All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, María Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, answers the question: Should daratumumab, carfilzomib, lenalidomide and dexamethasone combination become the new standard of care for lenalidomide refractory patients with relapsed/refractory multiple myeloma based on the CANDOR trial results?
María Victoria Mateos discusses the results of the late-breaking, phase III, randomized CANDOR trial, that was conducted in relapsed or refractory patients with myeloma. She explains the efficacy of the drug regimens in the patient population.
CANDOR study: should Dara-Kd become the new SOC for len refractory patients with RRMM?
MASTER trial | Monoclonal antibody-based quadruplet regimen (Dara-KRd) with MRD–based response-adapted therapy in patients with NDMM
Summary of Abstract #860 presented at ASH | Monoclonal antibody-based quadruplet regimen (daratumumab-KRd) with...
Phase III CANDOR study meets primary endpoint
The phase III CANDOR study comparing daratumumab (D) in combination with carfilzomib (K) and dexamethasone (d, KdD) to Kd alone, met its primary endpoint of PFS
Subscribe to get the best content related to multiple myeloma delivered to your inbox